Le Lézard
Classified in: Health
Subjects: RCL, CFG

Public Advisory - Recall of one lot of Jamp-Atorvastatin Calcium as some bottles may be labelled as containing 10 mg tablets, but contain 40 mg tablets


OTTAWA, ON, Aug. 27, 2022 /CNW/ -

Summary
Photos

Jamp-Atorvastatin Calcium 10 mg tablets (CNW Group/Health Canada)

Jamp-Atorvastatin Calcium 40 mg tablets (CNW Group/Health Canada)

Affected products

Product

Company

DIN

Lot

Expiry Date

Jamp-Atorvastatin Calcium

10 mg tablets

 

Jamp Pharma Corporation

02504197

D10776B

06/2023

Jamp-Atorvastatin Calcium

40 mg tablets

Jamp Pharma Corporation

02504219

D10776B

06/2023

 

Issue

Jamp Pharma Corporation is recalling one lot (D10776B) of Jamp-Atorvastatin Calcium after one bottle labelled to contain 10 mg tablets of Jamp-Atorvastatin Calcium was found to contain 40 mg tablets of Jamp-Atorvastatin Calcium.

Pharmacists may not recognize the error and accidentally repackage and dispense bottles to patients that are labelled as 10 mg atorvastatin calcium tablets (DIN 02504197), but incorrectly contain 40 mg atorvastatin calcium tablets.

Product from the affected lot was sold to pharmacies between May 2022 and August 2022.

Both the 10 mg and 40 mg atorvastatin calcium tablets are similar-looking white and oval shaped tablets; however, the 10 mg tablets have a "10" marked on one side while the 40 mg tablets have a "40" marked on one side. 

Atorvastatin calcium is a prescription drug in the class of statins used to lower cholesterol and other fats in the blood and for prevention of cardiovascular disease such as heart attacks.

Taking too much atorvastatin calcium or more than the prescribed amount for a long period of time (i.e., taking 40 mg of atorvastatin calcium instead of 10 mg atorvastatin calcium) can increase the risk of serious adverse events, including muscle pain or muscle weakness (i.e., rhabdomyolysis, a rare but serious adverse event associated with statins).

The Department is monitoring the company's recall and will inform the public if any new health risks are identified.

What you should do
Additional information for health care professionals:

Alert / recall type: Public Advisory
Category: Health products ? Drugs
Published by: Health Canada

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 04:00
May 17, 2024 Three studies demonstrate how Philips MCOT wearable ambulatory monitoring ECG and proprietary AI models applied to ECG digital biomarkers can help to improve diagnosis, reduce readmissions, and lower costs Amsterdam, the Netherlands...

at 04:00
Brainomix, a pioneer in artificial intelligence (AI) imaging solutions to enable precision medicine, is proud to announce the FDA clearance of...

at 04:00
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announced its presence at Heart Rhythm 2024, the Annual Meeting of the Heart Rhythm Society (HRS) in the U.S. At Heart Rhythm 2024, the Company will showcase its upper-arm blood...

at 03:00
Hypertension, or high blood pressure, affects one in three Europeans over the age of 30 and more than one billion people worldwide.  Hypertension is known as the "silent killer" because many people do not know they have it and, over time, it can lead...

at 03:00
At the Summit on Clean Cooking in Africa, World Resources Institute (WRI) and the Clean Cooking Alliance (CCA) announced a strategic partnership to further embed clean cooking into a broad range of sustainable development initiatives across the two...

at 02:00
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...



News published on and distributed by: